Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Social Anxiety Disorder
NCT00114127Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2004
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in Social Anxiety Disorder (SAD) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Liebowitz Social Anxiety Scale at 6 months. Started Jun 2004; status: completed.
02
Drugs
duloxetine
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT00114127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114127.